Drug Approval | September 28, 2024
FDA approves Bristol Myers Squibb’s Cobenfy
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Krsnaa Diagnostics receives LoI from RINPAS for radiology services
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
This approval reflects company’s unwavering commitment that the quality assurance
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India
Eugia Steriles receives EIR from USFDA for new injectable facility
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Subscribe To Our Newsletter & Stay Updated
